Literature DB >> 2358016

Tumor necrosis factor-alpha and interleukin 6 synergistically induce T cell growth.

R Kuhweide1, J Van Damme, J L Ceuppens.   

Abstract

T cells stimulated with phytohemagglutinin are dependent on monocyte-derived helper signals (e.g. interleukin (IL) 6 and IL 1) for their proliferation. In the present study the effect of recombinant tumor necrosis factor alpha (rTNF-alpha) as a helper signal for growth of highly purified peripheral blood human T cells stimulated with phytohemagglutinin was examined. TNF-alpha alone had a weak co-stimulatory effect, while a combination of TNF-alpha and IL 6 provided highly effective synergistic helper signals for T cell proliferation. The effect of TNF-alpha could not be ascribed to secondary induction of IL 1 production. The effect of TNF-alpha on T cell proliferation was also found to be independent of the autocrine T cell growth factors IL 2 and IL 4. This latter points to dissimilarity between IL 1 and TNF-alpha in the mechanism by which each of these two cytokines in combination with IL 6 promotes T cell proliferation. TNF-alpha, IL 6 and IL 1 thus seem to follow different pathways in their function as helper signals in T cell activation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2358016     DOI: 10.1002/eji.1830200511

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Tumor necrosis factor receptors in lymphoid tissues and lymphomas. Source and site of action of tumor necrosis factor alpha.

Authors:  B Ryffel; M Brockhaus; U Dürmüller; F Gudat
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

2.  Local effects of recombinant rat interleukin-6 on the peripheral nervous system.

Authors:  G Deretzi; S H Pelidou; L P Zou; C Quiding; J Zhu
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

3.  Tumour necrosis factor receptor distribution in human lymphoid tissue.

Authors:  B Ryffel; M Brockhaus; B Greiner; M J Mihatsch; F Gudat
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

4.  Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.

Authors:  Jingying Zhou; Allen Kl Cheung; Henggui Liu; Zhiwu Tan; Xian Tang; Yuanxi Kang; Yanhua Du; Haibo Wang; Li Liu; Zhiwei Chen
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

5.  Diminished T lymphocyte proliferative response to polyclonal mitogens in acute brucellosis patients.

Authors:  M Rodriguez-Zapata; M Alvarez-Mon; I Salmeron; A Prieto; L Manzano; O J Salmeron; J Carballido
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

6.  In vivo expression of interleukin-1 beta (IL-1 beta), IL-2, IL-4, IL-6, tumour necrosis factor-alpha and interferon-gamma in the fetal murine thymus.

Authors:  J Deman; M Van Meurs; E Claassen; C Humblet; J Boniver; M P Defresne
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

7.  Cytokine correlations in youth with tic disorders.

Authors:  E Carla Parker-Athill; Jared Ehrhart; Jun Tan; Tanya K Murphy
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-02-06       Impact factor: 2.576

8.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

9.  Role of interleukin-6 in the induction of protective T cells during mycobacterial infections in mice.

Authors:  R Appelberg; A G Castro; J Pedrosa; P Minóprio
Journal:  Immunology       Date:  1994-07       Impact factor: 7.397

10.  Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.

Authors:  Brian W C Tse; Kieran F Scott; Pamela J Russell
Journal:  Prostate Cancer       Date:  2012-12-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.